Twist Bioscience (TWST): Insider to Sell 23,747 Shares Worth $764K

Twist Bioscience Corp (TWST) filed a Form 144 reporting a proposed sale of 23,747 common shares with an aggregate market value of $764,344.69, representing part of shares acquired by restricted stock vesting on 10/01/2025.

Rhea-AI Filing Summary

Twist Bioscience Corp (TWST) filed a Form 144 reporting a proposed sale of 23,747 common shares with an aggregate market value of $764,344.69, representing part of shares acquired by restricted stock vesting on 10/01/2025. The filing lists the intended approximate sale date as 10/06/2025 on NASDAQ. It also discloses recent insider sales by Patrick Finn totaling 7,467 shares across 07/23/2025, 08/04/2025, 08/21/2025, and 10/02/2025 with combined gross proceeds visible in the table. The filer contact and CIK fields appear incomplete in the form, and no earnings or corporate operational details are included.

Positive

• 23,747 shares acquired by restricted stock vesting, indicating alignment of compensation with equity
• Full transaction details provided: broker, dates, share counts and gross value ($764,344.69)

Negative

• None.

Insights

Insider Trading Analyst

TL;DR: An executive received restricted stock that is now listed for sale, adding modest supply to the market.

The filing shows 23,747 shares acquired by restricted stock vesting on 10/01/2025 and proposed for sale on 10/06/2025 through Fidelity Brokerage Services. The aggregate value reported is $764,344.69, implying a single-event liquidity realization for the insider.

Risks and dependencies include the timing of execution and market liquidity; the amount equals about 0.039 of the reported outstanding shares (23,747 of 60,360,925), a small fraction unlikely to move market price by itself. Monitor subsequent Form 4 or 144 amendments within days for execution details.

Corporate Counsel (Securities)

TL;DR: The notice documents compliance with Rule 144 for a vesting-related sale and includes standard seller certifications.

The filer certifies absence of undisclosed material adverse information and lists the sale as compensation-related. The form shows broker information and prior open-market sales by an individual named Patrick Finn during 07/23/2025–10/02/2025, with gross proceeds reported per trade.

From a compliance standpoint, watch for a matching Form 4 that records actual sale execution and for any trading-plan disclosure indicating Rule 10b5-1 protection; if absent, advisors often expect prompt Form 4 filing within required timeframes.

FAQ

What does Twist Bioscience's (TWST) Form 144 report?

It reports a proposed sale of 23,747 common shares valued at $764,344.69, with an approximate sale date of 10/06/2025 on NASDAQ.

How were the shares acquired for the TWST sale?

The shares were acquired by restricted stock vesting on 10/01/2025 and payment is listed as compensation.

Who executed recent insider sales listed in the filing?

The filing shows recent sales by Patrick Finn on 07/23/2025, 08/04/2025, 08/21/2025, and 10/02/2025 totaling 7,467 shares with gross proceeds shown per trade.

Does the Form 144 include the filer CIK or contact details?

The form's CIK and submission contact fields appear incomplete or blank; full filer identity details are not provided in the content.

Will this sale materially dilute TWST shares outstanding?

The proposed sale of 23,747 shares is approximately 0.039 of the reported 60,360,925 outstanding shares, a small percentage that is not likely to cause material dilution by itself.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/06/2025 - 04:52 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001755970
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Twist Bioscience Corp
SEC File Number	001-38720
Address of Issuer	681 GATEWAY BLVD. SOUTH SAN FRANCISCO CALIFORNIA 94080
Phone	800-719-0671
Name of Person for Whose Account the Securities are To Be Sold	Finn Patrick John
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	23747	764344.69	60360925	10/06/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/01/2025	Restricted Stock Vesting	Issuer			23747	10/01/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Patrick Finn 681 Gateway Blvd South San Francisco CA 94080	Common	07/23/2025	2232	79773.02
Patrick Finn 681 Gateway Blvd South San Francisco CA 94080	Common	08/04/2025	3189	90453.11
Patrick Finn 681 Gateway Blvd South San Francisco CA 94080	Common	08/21/2025	1840	47774.13
Patrick Finn 681 Gateway Blvd South San Francisco CA 94080	Common	10/02/2025	206	6007.15

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	10/06/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jennifer Ruchti, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Patrick Finn
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)